Nitric oxide and pulmonary arterial pressures in pulmonary hypertension
- 1 October 2004
- journal article
- Published by Elsevier in Free Radical Biology & Medicine
- Vol. 37 (7) , 1010-1017
- https://doi.org/10.1016/j.freeradbiomed.2004.06.039
Abstract
No abstract availableKeywords
Funding Information
- U.S. Public Health Service (MO1-RR018390)
- National Institutes of Health (HL04265, HL60917, HL68863)
This publication has 35 references indexed in Scilit:
- Comparison of cadmium and enzyme-catalyzed nitrate reduction for determination of NO2−/NO3− in breath condensateClinica Chimica Acta; International Journal of Clinical Chemistry, 2003
- Primary pulmonary hypertension: an overview of epidemiology and pathogenesis.Cleveland Clinic Journal of Medicine, 2003
- Increased nitrotyrosine in exhaled breath condensate in cystic fibrosisEuropean Respiratory Journal, 2001
- Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertensionHeart, 2000
- Nitrite levels in breath condensate of patients with cystic fibrosis is elevated in contrast to exhaled nitric oxideThorax, 1998
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Role of Nitric Oxide in the Local Regulation of Pulmonary Vascular Resistance in HumansCirculation, 1996
- Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1995
- Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNature, 1987